At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 547 enrolled
Drug / intervention
5-mg Desloratadine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Intermittent Allergic Rhinitis (IAR)
In Brief
A Phase 3 clinical trial evaluating 5-mg Desloratadine and Placebo for Rhinitis, Allergic, Seasonal and Rhinitis, Allergic, Perennial. Completed, enrolled 547 participants.
Detailed Summary
This study will investigate the effectiveness of desloratadine in treating subjects with allergic rhinitis (AR) who meet the criteria for intermittent allergic rhinitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedDec 2006
Primary CompletionNov 2007
TodayJul 2026
First PostedDec 4, 2006
Enrollment StartAug 1, 2006
Primary CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.6 years ago
Interventions
5-mg Desloratadinedrug
5-mg Desloratadine tablet, once daily for 15 days
Placebodrug
Placebo tablet, once daily for 15 days